Avalon GloboCare Corp.

Real Estate Services
Real Estate

Prices are adjusted according to historical splits.

Avalon GloboCare Corp. Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$34.39 million
Book Value:
Revenue TTM:
$1.19 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Avalon GloboCare Corp. had its IPO on 2016-12-06 under the ticker symbol ALBT.

The company operates in the Real Estate sector and Real Estate Services industry. Avalon GloboCare Corp. has a staff strength of 5 employees.

Stock update

Shares of Avalon GloboCare Corp. opened at $2.1 at the start of the last trading session i.e. 2023-03-23.

The stocks traded within a range of $1.74 - $2.19, and closed at $1.83.

This is a -12.02% slip from the previous day's closing price.

A total volume of 62,233 shares were traded at the close of the day’s session.

In the last one week, shares of Avalon GloboCare Corp. have slipped by -25.91%.

Avalon GloboCare Corp.'s Key Ratios

Avalon GloboCare Corp. has a market cap of $34.39 million, indicating a price to book ratio of 9.4262 and a price to sales ratio of 35.6002.

In the last 12-months Avalon GloboCare Corp.’s revenue was $1.19 million with a gross profit of $354055 and an EBITDA of $-7183161. The EBITDA ratio measures Avalon GloboCare Corp.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Avalon GloboCare Corp.’s operating margin was -629.76% while its return on assets stood at -40.33% with a return of equity of -368.47%.

In Q3, Avalon GloboCare Corp.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 34.7%.

Avalon GloboCare Corp.’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.84 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Avalon GloboCare Corp.’s profitability.

Avalon GloboCare Corp. stock is trading at a EV to sales ratio of 35.3261 and a EV to EBITDA ratio of -5.5589. Its price to sales ratio in the trailing 12-months stood at 35.6002.

Avalon GloboCare Corp. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$12.91 million
Total Liabilities
$3.33 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Avalon GloboCare Corp. ended 2023 with $12.91 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.91 million while shareholder equity stood at $4.58 million.

Avalon GloboCare Corp. ended 2023 with $0 in deferred long-term liabilities, $3.33 million in other current liabilities, 609973.00 in common stock, $-60645040.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.94 million and cash and short-term investments were $3.94 million. The company’s total short-term debt was $44,880 while long-term debt stood at $4.56 million.

Avalon GloboCare Corp.’s total current assets stands at $4.45 million while long-term investments were $478362.00 and short-term investments were $0. Its net receivables were $122230.00 compared to accounts payable of $80585.00 and inventory worth $0.

In 2023, Avalon GloboCare Corp.'s operating cash flow was $1014.00 while its capital expenditure stood at $0.

Comparatively, Avalon GloboCare Corp. paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Avalon GloboCare Corp. stock is currently trading at $1.83 per share. It touched a 52-week high of $8.498 and a 52-week low of $8.498. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $2.95 and 200-day moving average was $4.52 The short ratio stood at 1.05 indicating a short percent outstanding of 0%.

Around 6718.5% of the company’s stock are held by insiders while 83% are held by institutions.

Frequently Asked Questions About Avalon GloboCare Corp.

The stock symbol (also called stock or share ticker) of Avalon GloboCare Corp. is ALBT

The IPO of Avalon GloboCare Corp. took place on 2016-12-06

Similar Industry Stocks (Real Estate Services)

Last Price
Cibl Inc. (CIBY)

Most Active

Last Price
Boxed Inc (BOXD)
Tesla Inc (TSLA)

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.


4400 Route 9 South, Freehold, NJ, United States, 07728